The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) included InnoCare’s ICP‑B794 and Hiteck Biological’s Aponermin in the “Care Program – Extension” pilot project, while Genhouse Bio’s GH56 was included in the pilot program to encourage the research and development of pediatric anti‑tumor drugs.
Contents
Policy Snapshot
| Item | Detail |
|---|---|
| Agency | CDE of the NMPA (China) |
| Action | Inclusion in expedited R&D pilot programs |
| “Care Program – Extension” Pilot | ICP‑B794 (InnoCare); Aponermin (Hiteck Biological) |
| Pediatric Oncology Pilot | GH56 (Genhouse Bio) |
| Announcement Date | 24 Sep 2026 |
| Therapeutic Focus | Oncology |
| Program Incentives | Specific support measures for each program not disclosed |
Selected Assets at a Glance
| Asset | Company | Modality | Target / Mechanism | Key Indication Focus | Program |
|---|---|---|---|---|---|
| ICP‑B794 | InnoCare | Antibody‑drug conjugate (ADC) | Humanized anti‑B7‑H3 mAb + proprietary payload via protease‑cleavable linker | Solid tumors – lung, esophageal, nasopharyngeal, HNSCC, prostate | Care Program – Extension |
| Aponermin | Hiteck Biological | Recombinant biologic (E. coli–expressed) | Allosteric human TRAIL; activates DR4/DR5 → extrinsic apoptosis | Relapsed/refractory multiple myeloma (NMPA‑approved, Nov 2023) | Care Program – Extension |
| GH56 | Genhouse Bio | Small molecule | MTA‑cooperative PRMT5 inhibitor; synthetic lethality in MTAP‑deficient tumors | Pediatric anti‑tumor development | Pediatric oncology R&D pilot |
Drug Profiles & Mechanisms of Action
ICP‑B794 (InnoCare) – Anti‑B7‑H3 ADC
- Molecule: Formed by conjugating a humanized anti‑B7‑H3 monoclonal antibody with a potent payload independently developed by InnoCare via a protease‑cleavable linker.
- Target: B7‑H3, an immune‑modulatory antigen broadly expressed across multiple solid tumors.
- Design Rationale: The cleavable‑linker ADC design is expected to reduce off‑target effects while concentrating payload delivery in tumors.
- Potential Indications: Treatment options for patients with solid tumors such as lung cancer, esophageal cancer, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and prostate cancer.
Aponermin (Hiteck Biological) – Recombinant Allosteric Human TRAIL
- Molecule: Recombinant allosteric human tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL, CPT), expressed by Escherichia coli.
- Mechanism: Binds to and activates death receptor 4 (DR4) and death receptor 5 (DR5) on tumor cell surfaces, triggering the intracellular Caspase cascade via the extrinsic apoptosis pathway to exert anti‑tumor effects.
- Regulatory Status: Approved for marketing by the NMPA in November 2023, in combination with thalidomide and dexamethasone, for adult patients with relapsed or refractory multiple myeloma who have previously received at least two systemic treatment regimens.
GH56 (Genhouse Bio) – MTA‑Cooperative PRMT5 Inhibitor
- Molecule: A novel MTA‑cooperative PRMT5 inhibitor (small molecule).
- Mechanism: Exerts a synthetic lethality effect in tumors with methylthioadenosine phosphorylase (MTAP) deficiency – effectively inhibiting symmetric dimethylarginine (SDMA) modification in MTAP‑deficient tumor cells and thereby inducing apoptosis.
- Selectivity: In MTAP wild‑type cells, GH56 demonstrates good selectivity in inhibiting SDMA modification and cell proliferation, showing potential to minimize damage to normal cells while effectively eliminating tumor cells.
- Pediatric Angle: Inclusion in the CDE’s pediatric pilot supports the development of anti‑tumor therapy for pediatric patients with MTAP‑deficient tumors (specific pediatric indications not disclosed).
Market Impact & Outlook
- Expedited Development Signal: Inclusion in CDE pilot programs reflects regulatory prioritization of these assets and is designed to accelerate the research, development, and access pathway for clinically urgent innovative therapies in China.
- Modality Diversity: The three selections – an ADC, a recombinant apoptotic ligand biologic, and a synthetic‑lethality small molecule – span the full innovation spectrum of modern oncology drug design.
- Pediatric Oncology Push: GH56’s inclusion highlights the CDE’s dedicated effort to stimulate pediatric anti‑tumor drug R&D, a historically underserved area where MTAP‑deficient malignancies represent a precision‑medicine opportunity.
- Lifecycle Value for Aponermin: Already NMPA‑approved in relapsed/refractory multiple myeloma, Aponermin gains additional regulatory support for continued development under the “Care Program – Extension.”
- Pipeline Catalysts: For InnoCare, Hiteck Biological, and Genhouse Bio, the designations strengthen the regulatory profiles of key assets and may support faster progression toward clinical and registrational milestones (timelines not disclosed).
- Execution Watch Items: Clinical advancement of ICP‑B794 across its targeted solid‑tumor indications, expansion of Aponermin’s post‑approval development, and initiation of pediatric‑focused studies for GH56.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory review, and commercialization potential of ICP‑B794, Aponermin, and GH56 under the CDE pilot programs. Inclusion in a pilot program does not guarantee approval. Actual results may differ materially due to risks including clinical setbacks, regulatory requirements, and competitive dynamics.-Fineline Info & Tech
